The epidemiology of complications

Diabetes Care

Volumn 25, Issue 5, 2002, Pages 924-932

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PROTEIN KINASE C; GLYCOSYLATED HEMOGLOBIN;

ARTERY CALCIFICATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTRON BEAM TOMOGRAPHY; EPIDEMIOLOGICAL DATA; HEALTH ECONOMICS; HEART LEFT VENTRICLE FAILURE; HOSPITAL COST; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; META ANALYSIS; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; WORLD HEALTH ORGANIZATION; ARTERIOSCLEROSIS; DIABETES MELLITUS; EPIDEMIOLOGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; STANDARD;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; EPIDEMIOLOGIC STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; OXIDATIVE STRESS; PROTEIN KINASE C;

EID: 0036580693     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.5.924     Document Type: Conference Paper

References (21)

1. Colhoun HM, Rubens MB, Underwood SR, Fuller JH: The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J Am Coll Cardiol 36:2160-2167, 2000
2. Schurgin S, Rich S, Mazzone T: Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 24:335-338, 2001
3. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219-227, 2000
4. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379, 2001
5. American Diabetes Association: Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 21:296-309, 1998
6. Klein R, Klein BEK, Moss SE, Cruikshanks KJ: The relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Int Med 154:2169-2178, 1994
7. Klein R, Klein BEK, Moss SE: Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 124:90-96, 1996
8. The Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practices in the DCCT. JAMA 276:1409-1415, 1996
9. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
10. Chaturvedi N, Sjolie AK, Stephenson JM: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: the EUCLID Study Group. Lancet 351:28-31, 1998
11. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317:703-713, 1998
12. Chew EY, Klein ML, Ferris FL: Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Arch Opthalmol 114:1079-1084, 1996
13. Chase HP, Lockspeiser T, Perry B: The impact of the DCCT and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 24:430-434, 2001
14. Pfeifer MA, Schumer MP, Gelber DA: Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 46 (Suppl. 2):S82-S89, 1997
15. Friedman EA: Advanced glycolated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 22 (Suppl 2):B65-B71, 1999
16. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, 1994
17. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98:2018-2026, 1996
18. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH 3rd, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM: (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro- 4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C β. J Med Chem 39:2664-2671, 1996
19. Aiello LP, Bursell SE, Clermont A: VEGF-induced retinal permeability is mediated by PKC in vivo and suppressed by an orally effective beta-isoform selective inhibitor. Diabetes 46:1473-1480, 1997
20. Sharma A, Kharb S, Chugh SN, Kakkar R, Singh GP: Evaluation of oxidative stress before and after control of glycemia and after vitamin E supplementation in diabetic patients. Metabolism 49:160-162, 2000
21. He C, Sabol J, Mitsuhashi T, Vlassara H: Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48:1308-1315, 1999